- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04985838
Helping Ease Anxiety and Depression Following Stroke Stage 3 (HEADS:UP)
HEADS: UP (Helping Ease Anxiety and Depression Following Stroke) Psychological Self-management Intervention: a Randomised Controlled Pilot Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
AIM To test full-study procedures and determine whether to proceed to a future definitive trial.
Objectives
- Test full-study procedures, including measurement logistics, randomisation, and check the direction of effect is in the expected direction.
- Identify potential resource (cost) implications of delivering HEADS: UP and potential impact on NHS utilisation.
- Determine whether to proceed to a future Phase III definitive trial.
METHODS
SETTING: HEADS: UP will be delivered online, via Zoom or MS Teams according to Trainer preference.
MBSR TRAINERS: Experienced MBSR trainers (n=1-4) will deliver HEADS: UP Online. They will meet the criteria for Mindfulness-Based Teachers and Good Practice Guidelines for Mindfulness-Based Supervisors of MBI Teachers. In addition, all trainers will undertake the HEADS: UP Train the Trainer training (6 hours across 2 sessions) prior to delivering HEADS: UP. The investigators will deliver the training to inform the MBI teachers about the HEADS: UP adaptations and online research processes, with input from an experienced MBSR/HEADS: UP trainer and a member of the Project Advisory group with first-hand experience of stroke. The investigators will encourage fidelity with the HEADS: UP manual and provide a logbook (paper or electronic according to preference) for recording any divergence, along with reasons.
RECRUITMENT METHODS: The investigators will use a UK-focused community-based recruitment strategy comprising social media (e.g. Twitter, Facebook, Instagram) and third sector organisations e.g. Stroke Association, DifferentStrokes, to recruit community-dwelling stroke survivors. When recruiting through third sector organisations the investigators will send gatekeepers project information leaflets (PILs); and consent forms for distribution to relevant (e)mail distribution lists. When recruiting online the investigators will email/post PILs and consent forms in response to expressions of interest. The investigators will document each expression of interest using a first contact form and assign a potential participant ID. Details collected at this stage include contact details for arranging screening, how the potential participant found out about the study for recruitment analysis, and whether they have previously received any information about HEADS: UP. If the potential participant has not previously received information, the investigators will post or email copies of the information and consent forms according to the potential participant's preference.
SAMPLE SIZE: Typically, MBSR is delivered to groups, 15-20 participants. To promote adherence, the investigators will deliver HEADS: UP to dyads (stroke survivor plus 'family/peer'), where possible. As attrition has been estimated in a previous stage testing MBSR at approximately 23%-44% (depending on mode of delivery), the investigators will aim to enrol at least n=90 stroke survivor participants to 6 groups i.e. 15 stroke survivors (who may/may not be partnered by a family member) per group, in 2 'waves' i.e. 2 groups recruited by September 2021 (n= 30 stroke survivor participants); 4 groups recruited by the mid January 2022 (n= 60 stroke survivor participants). Allowing for attrition of 23%-44%, this will leave between 8-12 stroke survivor participants per group (i.e. n=50-69) by the end of the study. This fulfils the recommended minimum number of n=50 participants for feasibility study sample size. Note: if participant numbers are too much for the small research team to manage within the time available, the investigators will stop recruitment after four groups i.e. recruitment n=60, with an estimated n=40 left in the study at the end. This reduced number is still in keeping with NIHR Research Design Service recommendations.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Glasgow (City Of)
-
Glasgow, Glasgow (City Of), United Kingdom, G4 0BA
- Glasgow Caledonian University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged ≥18 years
- Have had ≥1 stroke at least 3 months previously
Able to speak and understand conversational English DESIRABLE BUT NOT ESSENTIAL: Able to identify a family member* who would: like to take part and can speak and understand conversational English.
- Family member: we use an inclusive definition of 'family': 'a self-identified group of two or more individuals who consider themselves as 'family' e.g. spouse, parent, friend. When we refer to 'family' in this document our meaning extends beyond 'family', to friends, peers and volunteers/buddies.
Exclusion Criteria:
- Prior MBSR attendance in the last three years (as this may confound results)
- Current participant in another trial of a similar psychological self-management intervention
- Currently receiving treatment for PTSD (post traumatic stress disorder) or psychosis
- Disclosing suicidal ideation
- Cannot follow a 2-stage command e.g. Please spell your surname and then tell me the days of the week; Please count to six and then spell your first name.
- Scores <3 on the PHQ-4
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control
No intervention provided.
|
|
|
Experimental: Online HEADS: UP
A group-based Mindfulness Based Stress Reduction (MBSR) course adapted for people affected by stroke and delivered using a video communication platform e.g.
Zoom.
An informal introductory session in the first week is followed by 8 weekly sessions (2.5 hours, incorporating 30-minute comfort breaks).
A 6-hour silent retreat is offered in week 7.
An optional follow-up session is offered six-eight weeks after completion of the 9-week course.
|
A group-based Mindfulness Based Stress Reduction (MBSR) course adapted for people affected by stroke and delivered online using a video communication platform.
An introductory session in the first week is followed by 8 weekly sessions (2.5 hours, incorporating 30-minute comfort breaks).
A 6-hour silent retreat is offered in week 7.
An optional follow-up session is offered six-eight weeks after completion of the 9-week course.
Course materials include a manual (provided after the introductory session), weekly pre/post-session emails with instructions and information about joining the sessions and engaging in personal practice, including links to audio files to complement class-based sessions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Beck Depression Inventory II (change being assessed)
Time Frame: Weeks 0, 8, 20, 32 (assessing change)
|
The Beck Depression Inventory II is a 21-item self-report scale to assess the intensity of depression.
Each item is a list of four statements arranged in increasing severity about a symptom of depression.
Score range between 0-63 with higher score indicating greater severity.
|
Weeks 0, 8, 20, 32 (assessing change)
|
|
Beck Anxiety Inventory (change being assessed)
Time Frame: Weeks 0, 8, 20, 32 (assessing change)
|
The Beck Anxiety Inventory is a self-report 21-item scale for measuring anxiety.
The questions ask about symptoms of anxiety the subject has had during the past week.
Each question is scored between 0 (mild) and 3 (severe) and a total score will vary between 0-63.
Higher scores indicate more severe anxiety symptoms.
|
Weeks 0, 8, 20, 32 (assessing change)
|
|
Depression Anxiety Stress Scales (change being assessed)
Time Frame: Weeks 0, 8, 20, 32 (assessing change)
|
The Depression Anxiety Stress Scale is a 21-item version of the full 42-item scale, consisting of a set of three self-report scales designed to measure depression, anxiety and stress.
Each of the three DASS-21 scales contains 7 items.
Participants are asked to use 4-point severity/frequency scales to rate the extent to which they have experienced each state over the past week.
Scores for Depression, Anxiety and Stress are calculated by summing the scores for the relevant items and multiplying by two to produce the equivalent DASS-42 score.
Higher scores suggesting more severe difficulties.
|
Weeks 0, 8, 20, 32 (assessing change)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Short Form Stroke Impact Scale (change being assessed)
Time Frame: Weeks 0, 8, 20, 32 (assessing change)
|
Short Form Stroke Impact Scale is a self-report, health status measure for people affected by stroke.
It was designed to assess strength, hand function, activities of daily living, mobility, communication, emotion, memory and thinking, and participation.
The SF-SIS can be used both in clinical and research settings.
It contains 8 items across the 8 domains.
Each item is rated using a 5-point Likert scale with higher scores indicating lesser impairment.
|
Weeks 0, 8, 20, 32 (assessing change)
|
|
EQ-5D 5L (change being assessed)
Time Frame: Weeks 0, 8, 20, 32 (assessing change)
|
The 5-level EQ-5D version comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.
This decision results in a 1-digit number that expresses the level selected for that dimension.
The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
|
Weeks 0, 8, 20, 32 (assessing change)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Maggie Lawrence, PhD, Glasgow Caledonian University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HLS/NCH/20/038
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of MinnesotaCompletedDepression SymptomsUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Bekelu Teka WorkuJimma UniversityNot yet recruitingPrenatal Depression | Mental Health Related Quality of Life | Maternal Postpartum Depression | Paternal Postpartum DepressionEthiopia
Clinical Trials on HEADS: UP (Helping Ease Anxiety and Depression)
-
Glasgow Caledonian UniversityCompletedDepression | Stroke | Anxiety | CVA (Cerebrovascular Accident)United Kingdom
-
Glasgow Caledonian UniversityUniversity of Manchester; University of Strathclyde; Edinburgh Napier University and other collaboratorsCompletedDepression | Stroke | Anxiety | CVA (Cerebrovascular Accident)United Kingdom
-
Wenzhou Medical UniversityCompleted
-
San Diego State UniversityNational Institute of Mental Health (NIMH); Kaiser Permanente; OCHIN, Inc.Enrolling by invitationDepression, AnxietyUnited States
-
Lena ReuterskioldCompletedAnxiety Depression | CBTSweden
-
Karolinska InstitutetNot yet recruitingDepression | Anxiety | Mental Illness
-
Henan Cancer HospitalRecruitingDepression | Anxiety | Malignant TumorChina
-
Huazhong University of Science and TechnologyRecruiting
-
Vanderbilt University Medical CenterCompleted